SCHEMBL3564612

SCHEMBL3564612

CC(=O)c1ccc2ccc(NC(=O)OC(C)(C)C)c(Br)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP17A1 P05093 3/20 0.42
▸ PLAU P00749 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP2A6 P11509 1/20 0.37
▸ LCK P06239 3/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ NQO2 P16083 1/20 0.36
▸ PRKCI P41743 1/20 0.35
▸ KAT6A Q92794 1/20 0.35
▸ AKR1C3 P42330 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565251 0.89 KDM4E (0.41) CYP17A1PLAUALDH1A1HPGDLCK
SCHEMBL2400479 0.81 NCEH1 (0.46) ALDH1A1MAPTHPGDRXFP1NQO2
SCHEMBL29811032 0.81 NCEH1 (0.46) ALDH1A1MAPTHPGDRXFP1NQO2
SCHEMBL27679904 0.81 MAPT (0.44) ALDH1A1MAPTHPGDCYP2A6PRKCI
SCHEMBL3565771 0.80 NCEH1 (0.43) NQO2AAK1
SCHEMBL3555734 0.80 LCK (0.48) CYP17A1PLAUALDH1A1HPGDLCK
SCHEMBL3570368 0.80 GPR119 (0.45) ALDH1A1MAPTHPGDNQO2KAT6A
SCHEMBL28655699 0.79 NCEH1 (0.48) LCKCA12CA1CA9RXFP1
SCHEMBL28432480 0.78 CYP17A1 (0.46) CYP17A1MAPTCA12CA1CA9
SCHEMBL28783343 0.77 KCNQ4 (0.43) CYP17A1CA12CA1CA9RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 — — US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A CYP17A1 393/4885PLAU 3927/4885ALDH1A1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback